Rare Kidney Diseases benzinga.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from benzinga.com Daily Mail and Mail on Sunday newspapers.
ABIONYX Pharma: ABIONYX Announces Positive Clinical Results From CER-001 in the LCAT Deficiency Disease Published in the Annals of Internal Medicine
Confirmation of the breakthrough therapy status of CER-001 in kidney and ophthalmic diseases
Systemic mechanism of action of CER-001
ABIONYX Pharma (
FR0012616852 ABNX PEA PME eligible), a new generation biotech company dedicated to innovative therapies for patients, today announces positive clinical results from CER-001 in the LCAT (lecithin-cholesterol acyltransferase) deficiency disease published in the
Annals of Internal Medicine
The patient with inherited mutations in the lecithin-cholesterol acyltransferase (LCAT) gene developed glomerulopathy and corneal lipid deposits and displayed very low circulating levels of high-density lipoprotein (HDL) and apoA-I. The patient was treated with CER-001, an apoA-I-containing HDL mimetic, to help in preventing rapidly progressive kidney failure.
Agenda for Calliditas virtual R&D Day on January 20, 2021
News provided by
Share this article
Calliditas Therapeutics AB (publ) ( Calliditas ) (Nasdaq OMX - CALTX) (NASDAQ - CALT)
today announced the program for the upcoming virtual R&D Day for investors, analysts and journalists on January 20, 2021, which will take place between 1pm and 5pm CET. The R&D Day will feature presentations from executive management and Key Opinion Leaders and will be webcast live and accessible at:
1:00pm
Professor Jonathan Barratt
CMO Dr Richard Phillipson
Professor Jonathan Barratt
2:20pm
2:40pm
Head of North America Commercial, Andrew Udell, & Vice President Market Access, Christopher Ngai